TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

Contributed by: Business Wire

Logo

Tags

Neurology

Biotechnology

Pharmaceutical

General Health

Health

Mental Health

Clinical Trials

Other Health

UK Marketing Authorisation Application

More Like This

Professor Claude Wischik (Photo: Business Wire)

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March

Co-founder and CEO, Professor Claude Wischik (Photo: Business Wire)

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial

Lecanemab licensed for adult patients in the early stages of Alzheimer’s disease

PR Newswire associated0

Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But Condemns Decision to Deny NHS Access

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain